|
Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy Clinical research trials and Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy. Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy clinical trial. Human subjects often receive the most effective healthcare possible for their Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy  Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
For Condition: recurrent prostate cancer,stage 4 prostate cancer,adenocarcinoma of the prostate
Status: No longer recruiting
Sponsor(s): Eastern Cooperative Oncology Group , National Cancer Institute (NCI)
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. It is not yet known which treatment regimen is more effective in treating metastatic prostate cancer. PURPOSE: Randomized phase II trial to compare the effectiveness of combination chemotherapy with that of chemotherapy plus biological therapy in treating patients who have progressive or metastatic prostate cancer that has not responded to hormone therapy.
Details: OBJECTIVES: - Compare the effect of estramustine, mitoxantrone, and vinorelbine vs isotretinoin, interferon alfa, and paclitaxel on PSA response in patients with metastatic hormone-refractory prostate cancer. - Determine the toxic effects of each regimen in this patient population. - Determine the effect of each regimen on pain, fatigue, and quality of life in these patients. - Determine the objective response rate among the subset of patients who have bidimensionally measurable disease to each regimen after treatment. - Determine the effect of each regimen on peripheral blood mononuclear cell BCL-2 in these patients. OUTLINE: This is a randomized, multicenter study. Patients are stratified according to disease (measurable vs nonmeasurable and elevated PSA). Patients are randomized to one of two treatment arms. - Arm I: Patients receive vinorelbine IV over 10 minutes on days 2 and 9 followed by mitoxantrone IV over 10 minutes on day 2 only. Oral estramustine is administered every 12 hours on days 1-5. Courses repeat every 3 weeks in the absence of unacceptable toxicity, disease progression, or administration of the maximum cumulative dose of mitoxantrone. - Arm II: Patients receive oral isotretinoin and interferon alfa subcutaneously on days 1 and 2 and paclitaxel IV over 1 hour on day 2 weekly for 6 weeks. Courses repeat every 8 weeks in the absence of unacceptable toxicity or disease progression. Quality of life is assessed at baseline, on day 2 of courses 2, 4, and 6 (arm I), on day 22 of course 1 and day 1 of courses 2 and 3 (arm II), and then at completion of treatment. Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter. PROJECTED ACCRUAL: A total of 70-114 patients (35-57 per arm) will be accrued for this study within 14-23 months.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed adenocarcinoma of the prostate - Evidence of progressive metastatic disease (e.g., bone, pelvic mass, lymph node, liver or lung metastases) - Radiologic evidence of hydronephrosis only does not constitute evidence of metastatic disease - Must not have an elevated serum alkaline phosphatase or PSA level as only evidence of disease - If bone metastases only (i.e., lacking soft tissue disease), must have PSA level of at least 20 ng/mL - If soft tissue metastases and/or visceral disease, must have either bidimensionally measurable disease or PSA level of at least 20 ng/mL - Must have had prior bilateral orchiectomy or other primary hormonal therapy (e.g., estrogen therapy or LHRH blocker plus flutamide) with evidence of treatment failure - No carcinomatous meningitis or brain metastases PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - ECOG 0-2 Life expectancy: - Not specified Hematopoietic: - WBC at least 4,000/mm^3 - Granulocyte count at least 2,000/mm^3 - Platelet count at least 100,000/mm^3 Hepatic: - See Disease Characteristics - Bilirubin no greater than 1.5 mg/dL - SGOT/SGPT no greater than 2 times upper limit of normal Renal: - Creatinine no greater than 2.0 mg/dL OR - Creatinine clearance at least 50 mL/min Cardiovascular: - No active angina pectoris - No New York Heart Association class III or IV heart disease - No myocardial infarction within the past 6 months - No deep venous thrombosis - LVEF at least 50% by MUGA Other: - Fertile patients must use effective contraception during and for 1 month after study - Prior malignancy allowed provided curatively treated and disease free for appropriate time period for specific cancer - No other serious medical illness or active infection that would preclude protocol therapy - No concurrent prolonged exposure to sunlight - No concurrent alcohol consumption PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - No prior chemotherapy, including neoadjuvant chemotherapy or single-agent estramustine Endocrine therapy: - See Disease Characteristics - If no prior bilateral orchiectomy, must continue LHRH agonist therapy (e.g., depot leuprolide or goserelin) - At least 4 weeks since prior flutamide or flutamide with evidence of progressive disease - At least 6 weeks since prior bicalutamide with evidence of progressive disease Radiotherapy: - More than 4 weeks since prior radiotherapy - No prior strontium chloride Sr 89, samarium Sm 153 lexidronam pentasodium, or other radioisotope therapies Surgery: - See Disease Characteristics Other: - Recovered from all toxic effects due to prior treatment for prostate cancer - No concurrent milk, milk products, antacids, calcium-containing drugs, or any food with estramustine (arm I only) - No concurrent vitamin supplements containing vitamin A (arm II only)
Total Enrollment:
Location and Contact Information:
Overall Study Official:
RobertDiPaola, Study Chair, Cancer Institute of New Jersey
CCOP - Kalamazoo
Kalamazoo, Michigan, 49007-3731
United States
Veterans Affairs Medical Center - Atlanta (Decatur)
Decatur, Georgia, 30033
United States
CCOP - St. Vincent Hospital Cancer Center, Green Bay
Green Bay, Wisconsin, 54307-3453
United States
CCOP - Northern New Jersey
Hackensack, New Jersey, 07601
United States
Tufts - New England Medical Center
Boston, Massachusetts, 02111
United States
CCOP - Colorado Cancer Research Program, Incorporated
Denver, Colorado, 80224
United States
CCOP - Geisinger Clinic and Medical Center
Danville, Pennsylvania, 17822-2001
United States
CCOP - Merit Care Hospital
Fargo, North Dakota, 58122
United States
Mayo Clinic Cancer Center
Rochester, Minnesota, 55905
United States
Emory University Hospital - Atlanta
Atlanta, Georgia, 30322
United States
CCOP - Metro-Minnesota
St. Louis Park, Minnesota, 55416
United States
Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903
United States
Medical College of Wisconsin Cancer Center
Milwaukee, Wisconsin, 53226-3596
United States
CCOP - Sioux Community Cancer Consortium
Sioux Falls, South Dakota, 57104
United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111
United States
CCOP - Carle Cancer Center
Urbana, Illinois, 61801
United States
Ireland Cancer Center
Cleveland, Ohio, 44106-5065
United States
CCOP - Toledo Community Hospital
Toledo, Ohio, 43623-3456
United States
MBCCOP-Our Lady of Mercy Cancer Center
Bronx, New York, 10466
United States
Additional Information:
Study ID Numbers: CDR0000067865; E-3899
Study Start Date:
Record last reviewed: December 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00005847
Other Adenocarcinoma Of The Prostate Studies:
1. Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Prostate Cancer
2. Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer
3. Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer
4. Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
5. Combination Chemotherapy in Treating Pain in Patients With Hormone Refractory Metastatic Prostate Cancer
Related Studies:
Other adenocarcinoma of the prostate Clinical Trials
Other Illinois Clinical Trials
Other Urbana Clinical Trials
Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
|
|
|
|
|
|
|
|
